Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for sgen
+0.20 (0.31%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 64.29 - 65.51
52 week 28.32 - 75.36
Open 64.93
Vol / Avg. 519,080.00/904,798.00
Mkt cap 9.30B
P/E     -
Div/yield     -
EPS -0.99
Shares 141.50M
Beta 2.25
Inst. own 98%
Feb 7, 2017
Q4 2016 Seattle Genetics Inc Earnings Release (Estimated)
Jan 9, 2017
Seattle Genetics Inc at JPMorgan Healthcare Conference (Q&A Session)
Jan 9, 2017
Seattle Genetics Inc at JPMorgan Healthcare Conference
Dec 5, 2016
Seattle Genetics Inc Analyst and Investor Event at American Society Annual Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -52.38% -33.51%
Operating margin -53.05% -34.13%
EBITD margin - -34.13%
Return on average assets -26.20% -16.17%
Return on average equity -34.12% -21.23%
Employees 759 -
CDP Score - -


21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Darren S. Cline Executive Vice President - Commercial
Age: 52
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer, Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Dennis Benjamin Senior Vice President - Translational Research
Bio & Compensation  - Reuters
Robert J. Lechleider M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Chief Technical Officer
Age: 55
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 47
Bio & Compensation  - Reuters